Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 27;15(3):386-392.
doi: 10.4254/wjh.v15.i3.386.

Emerging role of engineered exosomes in nonalcoholic fatty liver disease

Jian Ding  1 , Chen Xu  1 , Ming Xu  1 , Xiao-Yue He  2 , Wei-Na Li  3 , Fei He  4
Affiliations
Review

Emerging role of engineered exosomes in nonalcoholic fatty liver disease

Jian Ding et al. World J Hepatol. .

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. NAFLD comprises a continuum of liver abnormalities from nonalcoholic fatty liver to nonalcoholic steatohepatitis, and can even lead to cirrhosis and liver cancer. However, a well-established treatment for NAFLD has yet to be identified. Exosomes have become an ideal drug delivery tool because of their high transmissibility, low immunogenicity, easy accessibility and targeting. Exosomes with specific modifications, known as engineered exosomes, have the potential to treat a variety of diseases. Here, we review the treatment of NAFLD with engineered exosomes and the potential use of exosomes as biomarkers and therapeutic targets for NAFLD.

Keywords: Engineered exosome; Exosome; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All the authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1
Figure 1
Diagram shows the correlation between nonalcoholic fatty liver disease and engineered exosome. MVB: Multivesicular body; EV: Extracellular vesicles; NASH: Nonalcoholic steatohepatitis; NAFL: Nonalcoholic fatty liver; STAT3: Signal transducer and activator of transcription 3; RISC: RNA-induced silencing complex; MST1: Mammalian STE20-like kinase 1; USP7: Ubiquitin specific peptidase 7; KLF3: Kruppel-like factor 3; PINK: PETN induced kinase 1; PI3K: Phosphatidylinositol-4,5-Bisphosphate 3-Kinase; Akt: Protein kinase B.
See this image and copyright information in PMC

References

    1. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20. - PubMed
    1. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212–2224. - PubMed
    1. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367 - PMC - PubMed
    1. Wang W, Zhu N, Yan T, Shi YN, Chen J, Zhang CJ, Xie XJ, Liao DF, Qin L. The crosstalk: exosomes and lipid metabolism. Cell Commun Signal. 2020;18:119. - PMC - PubMed
    1. Nakao Y, Amrollahi P, Parthasarathy G, Mauer AS, Sehrawat TS, Vanderboom P, Nair KS, Nakao K, Allen AM, Hu TY, Malhi H. Circulating extracellular vesicles are a biomarker for NAFLD resolution and response to weight loss surgery. Nanomedicine. 2021;36:102430. - PMC - PubMed